Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicentre Phase 2 Study to Evaluate the Safety and Tolerability of Subcutaneous MOR106 Administered Concomitantly With Topical Corticosteroids for Eight Weeks, in Adult Subjects With Moderate to Severe Atopic Dermatitis

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicentre Phase 2 Study to Evaluate the Safety and Tolerability of Subcutaneous MOR106 Administered Concomitantly With Topical Corticosteroids for Eight Weeks, in Adult Subjects With Moderate to Severe Atopic Dermatitis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MOR 106 (Primary) ; Corticosteroids
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Acronyms GECKO
  • Sponsors Galapagos NV

Most Recent Events

  • 14 Nov 2019 Planned End Date changed from 1 Jun 2020 to 1 Mar 2020.
  • 14 Nov 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Mar 2020.
  • 28 Oct 2019 Status changed from recruiting to discontinued. The decision is based on the interim analysis performed on IGUANA trial (NCT03568071) which detected a low probability to meet the primary endpoint of the study (EASI score). The decision was based on a lack of efficacy and not on safety concerns.endpoint of the study (EASI score). The decision was based on a lack of efficacy and not on safety concerns.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top